Elevidys® (delandistrogene moxeparvovec-rokl)

BL 125781

Elevidys® (delandistrogene moxeparvovec-rokl)

BL 125781

U.S. License Holder:

Sarepta Therapeutics

Date of License:

June-22-2023

Last Update:

July-31-2025

approved_indications FDA-Approved Indications

ELEVIDYS (delandistrogene moxeparvovec-rokl) is an adeno-associated virus vector-based gene therapy indicated in individuals at least 4 years of age:

For the treatment of Duchenne muscular dystrophy (DMD) in patients who are ambulatory and have a confirmed mutation in the DMD gene;

For the treatment of DMD in patients who are non-ambulatory and have a confirmed mutation in the DMD gene.

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2024-00580

U.S. Patent No.
11,680,274 (Method of Increasing the Function of an AAV Vector)

Patent Owner
Trustees of the University of Pennsylvania; REGENXBIO Inc.

Petitioner(s)
Sarepta Therapeutics, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1, 3-6, 8

Claim Types Challenged Under § 103
Composition of Matter Formulation

§ 103 Challenge Instituted
Y

IPR Status
Instituted, Pending

IPR2025-01194

U.S. Patent No.
9,051,542 (Compositions and Methods to Prevent AAV Vector Aggregation)

Patent Owner
Genzyme Corp.

Petitioner(s)
Sarepta Therapeutics, Inc.; Sarepta Therapeutics Three, LLC

§ 102 Challenge
N

§ 103 challenge
Y: Claims 3-6

Claim Types Challenged Under § 103
Formulation

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

IPR2025-01195

U.S. Patent No.
7,704,721 (Compositions and Methods to Prevent AAV Vector Aggregation)

Patent Owner
Genzyme Corp.

Petitioner(s)
Sarepta Therapeutics, Inc.; Sarepta Therapeutics Three, LLC; Catalent, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-4, 6-7, 11

Claim Types Challenged Under § 103
Manufacturing

§ 103 Challenge Instituted
Awaiting Institution Decision

IPR Status
Awaiting Institution Decision

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:19-cv-02316 (D. Del.)

U.S. Patent Nos.
8,697,443 (Cell Culture Methods and Devices Utilizing Gas Permeable Materials) 9,441,192 (Cell Culture Methods and Devices Utilizing Gas Permeable Materials)

Plaintiffs
Wilson Wolf Manufacturing Corporation

Defendants
Sarepta Therapeutics, Inc.

Status
Stipulated Dismissal

BPCIA
N

1:20-cv-01226 (D. Del.)

U.S. Patent Nos.
10,526,617 (Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby)

Plaintiffs
REGENXBIO Inc.; Trustees of the University of Pennsylvania

Defendants
Sarepta Therapeutics, Inc.; Sarepta Therapeutics Three, LLC; Catalent, Inc.

Federal Circuit Appeal(s)
24-1408

Status
Summary Judgment: Patent Invalid- Ineligible Subject Matter under Section 101; Federal Circuit Appeal Pending

BPCIA
N

1:23-cv-00667 (D. Del.)

U.S. Patent Nos.
11,680,274 (Method of Increasing the Function of an AAV Vector)

Plaintiffs
REGENXBIO Inc.; Trustees of the University of Pennsylvania

Defendants
Sarepta Therapeutics, Inc.; Sarepta Therapeutics Three, LLC; Catalent, Inc.

Status
Stayed Pending IPR2024-00580

BPCIA
N

1:24-cv-00882 (D. Del.)

U.S. Patent Nos.
7,704,721 (Compositions and Methods to Prevent AAV Vector Aggregation) 9,051,542 (Compositions and Methods to Prevent AAV Vector Aggregation)

Plaintiffs
Genzyme Corporation

Defendants
Sarepta Therapeutics, Inc.; Sarepta Therapeutics Three, LLC

Status
Case Ongoing

BPCIA
N

Related News

Venable’s BiologicsHQ Monthly Injection – June 2025
Robert S. Schwartz, Ph.D.
July 16, 2025
Sarepta Files Two IPRs Against Genzyme’s Patents Gene Therapy Elevidys® Allegedly Infringes
Robert S. Schwartz, Ph.D.
June 27, 2025
Stipulated Dismissal of Gene Therapy Elevidys® Manufacturing Litigation
Robert S. Schwartz, Ph.D.
February 24, 2025
Venable’s BiologicsHQ Monthly Injection – July 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
August 10, 2024
Genzyme Files Complaint Against Sarepta Concerning Gene Therapy Elevidys®
Monica Chou Robert S. Schwartz, Ph.D.
August 8, 2024
Venable’s BiologicsHQ Monthly Injection – February 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
March 13, 2024

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha